Xanthine oxidoreductase (XOR) inhibitors, allopurinol, febuxostat, and topiroxostat are
hyperuricemia and gout therapeutic drugs, which were supposed to be same. However, it …

Background Allopurinol is used to treat hyperuricemia and gout. It is metabolized to
oxypurinol by xanthine oxidase (XO), and aldehyde oxidase (AO). Allopurinol and …

What is known and objective There are no clinical reports that have compared topiroxostat, a
selective xanthine oxidase inhibitor, with allopurinol in serum urate‐lowering efficacy. The …

Topiroxostat, a xanthine oxidoreductase (XOR) inhibitor, has been shown to decrease the
urinary albumin-to-creatinine ratio compared with placebo in hyperuricemic patients with …

Gout patients receiving a combination of allopurinol and furosemide require higher
allopurinol doses to achieve the target serum urate (SU) of< 6 mg/dl (Stamp et al., 2012)[1] …

Hyperuricemia, excess of uric acid in the blood, is a clinical problem that causes gout and is
also considered a risk factor for cardiovascular disease. The enzyme xanthine oxidase (XO) …

Background: Allopurinol has been widely used for the treatment of hyperuricemia, however,
it may be associated with various adverse effects. Febuxostat has been identified as a …

The purine analogue, allopurinol, has been in clinical use for more than 30 years as an
inhibitor of xanthine oxidase (XO) in the treatment of hyperuricemia and gout. As …

Objective: Febuxostat is more effective/superior to Allopurinol in reducing the serum uric
acid (SUA) level in the treatment of hyperuricemic with gout. Methods: This randomized …

Uric acid is the final oxidation product of purine metabolism in humans. Xanthine
oxidoreductase (XOR) catalyzes oxidative hydroxylation of hypoxanthine to xanthine to uric …